Efficacy and safety of lesinurad for the treatment of hyperuricemia in gout

Efficacy and safety of lesinurad for the treatment of hyperuricemia in gout

The aim of this review is to present current evidence about the efficacy and safety of lesinurad in combination with xanthine oxidase inhibitors (XOIs) in the treatment of hyperuricemia in patients with gout. Gout is the most common inflammatory form of arthritis. It is caused by an elevated concent...

Full description

Bibliographic Details
Main Authors:	Fernando Pérez-Ruiz, Tim Jansen, Anne-Katrin Tausche, Mónica Juárez-Campo, Ravichandra Karra Gurunath, Pascal Richette
Format:	Article
Language:	English
Published:	BioExcel Publishing Ltd 2019-05-01
Series:	Drugs in Context
Subjects:	allopurinol febuxostat gout hyperuricemia lesinurad serum uric acid levels urate lowering uric acid transporter 1
Online Access:	https://www.drugsincontext.com/efficacy-and-safety-of-lesinurad-for-the-treatment-of-hyperuricemia-in-gout

Similar Items

UPDATED EULAR GUIDELINES FOR THE MANAGEMENT OF GOUT. COMMENTS ON CERTAIN ITEMS
by: M. S. Eliseev
Published: (2018-01-01)

Commentaries on the updated American College of Rheumatology guidelines for the management of gout. Urate-lowering drugs (Part 1)
by: M. S. Eliseev
Published: (2020-09-01)

Uric acid, gout and cardiovascular diseases: prospects for the use of urat-lowering medications
by: M. S. Eliseev, et al.
Published: (2019-08-01)

Comorbidity in gout and hyperuricemia: prevalence, causes, prospects of urate lowering therapy
by: M S Eliseev, et al.
Published: (2019-05-01)

Efficacy and safety during extended treatment of lesinurad in combination with febuxostat in patients with tophaceous gout: CRYSTAL extension study
by: Nicola Dalbeth, et al.
Published: (2019-01-01)

Modern paradigm of treatment of hyperuricemia and gout in comorbid patients with the development of cardio-vascular pathology
by: V. I. Mazurov, et al.
Published: (2020-12-01)

Gout: objective, indications and adherence to uratelowering therapy
by: V. V. Tsurko, et al.
Published: (2019-03-01)

Moving the Needle: Improving the Care of the Gout Patient
by: Jon Golenbiewski, et al.
Published: (2019-03-01)

The problems associated with the treatment of chronic hyperuricaemia in Serbia
by: Milosavljević Miloš N., et al.
Published: (2016-01-01)

The problems associated with the treatment of chronic hyperuricaemia in Serbia
by: Milosavljević Miloš N., et al.
Published: (2017-01-01)

To treat or not to treat asymptomatic hyperuricemia
by: Hamid Mustafa
Published: (2014-01-01)

The Role of ABCG2 in the Pathogenesis of Primary Hyperuricemia and Gout—An Update
by: Robert Eckenstaler, et al.
Published: (2021-06-01)

Why Does Hyperuricemia Not Necessarily Induce Gout?
by: Wei-Zheng Zhang
Published: (2021-02-01)

The pattern of allopurinol prescription in a university hospital practice
by: Sahar Ahmed Saad, et al.
Published: (2020-09-01)

NEW OPPORTUNITIES FOR CORRECTION OF HYPERURICEMIA IN GOUT
by: Svetlana Evgenyevna Myasoedova, et al.
Published: (2009-12-01)

The development of an effective synthetic route of lesinurad (RDEA594)
by: Qing Meng, et al.
Published: (2017-09-01)

Research status of genes related to primary gout and hyperuricemia
by: Bai Xue, et al.
Published: (2019-08-01)

FEBUXOSTAT FOR TREATMENT OF CHRONIC HYPERURICEMIA IN GOUT PATIENTS
by: M. S. Petrova, et al.
Published: (2017-11-01)

Hyperuricemia, gout and high cardiovascular risk - how to manage them in clinical practice
by: V V Fomin, et al.
Published: (2019-12-01)

INTERACTION OF HYPERURICEMIA AND HYPERLIPIDEMIA IN MALE PATIENTS WITH PRIMARY GOUT
by: D. A. Nabiyeva, et al.
Published: (2016-05-01)

Evaluation of a 12-week allopurinol-lowering therapy in combination with the non-steroidal anti-inflammatory drug meloxicam in patients with gout
by: Margarita A. Gromova, et al.
Published: (2020-07-01)

Risk factors for primary gout and hyperuricemia
by: Xiang-Lin Yin, et al.
Published: (2020-10-01)

Renal affection in gout
by: Il'ya Vadimovich Egorov, et al.
Published: (2012-01-01)

Chronic kidney disease: the role of hyperuricemia and the possibility of urate-lowering therapy
by: M. S. Eliseev
Published: (2018-04-01)

Efficacy and safety of febuxostat extended release and immediate release in patients with gout and moderate renal impairment: phase II placebo-controlled study
by: Lhanoo Gunawardhana, et al.
Published: (2018-05-01)

Asymptomatic hyperuricemia: secret relationships, invisible effects and potential complications
by: I. Yu. Golovach, et al.
Published: (2021-01-01)

Main factors of gender dimorphism of gout (estrogens and diuretics vs alcohol and genetics)
by: Viktoriya Georgievna Barskova, et al.
Published: (2011-05-01)

USE OF HERBAL REMEDY URISAN AS BASIC THERAPY FOR GOUT
by: Tamila Nilovna Khalfina, et al.
Published: (2010-06-01)

USE OF HERBAL REMEDY URISAN AS BASIC THERAPY FOR GOUT
by: Tamila Nilovna Khalfina, et al.
Published: (2010-06-01)

Systemic Urate Deposition: An Unrecognized Complication of Gout?
by: Puja Khanna, et al.
Published: (2020-10-01)

THE HERBAL COMPLEX URISAN IS THE HELP TO A PHYSICIAN TREATING A PATIENT WITH GOUT
by: I I Polskaya, et al.
Published: (2009-09-01)

Circulating microRNA alternations in primary hyperuricemia and gout
by: Jana Bohatá, et al.
Published: (2021-07-01)

Treatment of asymptomatic hyperuricemia in chronic kidney disease: A new target in an old enemy – A review
by: Maria Erika G. Ramirez, et al.
Published: (2017-09-01)

Experience with febuxostat in a patient with severe disabling gout
by: M. S. Eliseev, et al.
Published: (2017-09-01)

Discovery of a Flexible Triazolylbutanoic Acid as a Highly Potent Uric Acid Transporter 1 (URAT1) Inhibitor
by: He Tian, et al.
Published: (2016-11-01)

Chinese Multidisciplinary Expert Consensus on the Diagnosis and Treatment of Hyperuricemia and Related Diseases
by: Multidisciplinary Expert Task Force on Hyperuricemia and Related Diseases
Published: (2017-01-01)

Geographical distribution of hyperuricemia in mainland China: a comprehensive systematic review and meta-analysis
by: Jiayun Huang, et al.
Published: (2020-11-01)

Management of hyperuricemia in gout: focus on febuxostat
by: Mattheus K Reinders, et al.
Published: (2010-01-01)

Behavioral Characteristics of Gout Patients and Their Impact on the Results of Urate Lowering Therapy
by: J. Chen, et al.
Published: (2021-04-01)

Comments on the updated recommendations of the American College of Rheumatology (ACR) for the treatment of gout. Lifestyle (part 2)
by: M. S. Eliseev
Published: (2021-04-01)

Cannot write session to /tmp/vufind_sessions/sess_9k5oo0p71dm5slttfdfmkhs1fh